Immunology companies study and manipulate the immune system to develop therapies, diagnostics and research tools. The field plays a central role in areas such as cancer, infectious disease, autoimmune disorders and vaccine development.
This category includes companies working on:
Browse 182 UK immunology companies below.
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets prescription medicines across oncology, neurology, immunology, endocrinology, and fertility. Key products include Erbitux for colorectal and…
Native mass spectrometry platform for small molecule drug discovery
OMass Therapeutics is a biotechnology company developing small molecule therapeutics against membrane proteins, GPCRs, and intracellular complexes that have historically been difficult to drug. Its proprietary platform combines native mass spectrometry, novel biochemistry, and custom chemistry to interrogate protein…
Clinical-stage oncology biopharma developing the bispecific antibody ivonescimab
Summit Therapeutics is a clinical-stage oncology company with UK research operations originating from VASTox, a University of Oxford spin-out. The company's lead candidate, ivonescimab, is a bispecific antibody targeting PD-1 and VEGF, in-licensed from Akeso and now in multiple global Phase III trials across non-small…
Human biospecimen collection and supply for drug discovery and research
Clinical Trials Laboratory Services is a specialist supplier of human biological specimens to pharmaceutical, biotechnology, and academic research customers. Operating from an HTA-licensed donor centre in London, the company collects whole blood, serum, plasma, immune cell subsets, leukopaks, and other biofluids from…
Life science campus co-locating early-stage companies with discovery research
Babraham Research Campus is a 430-acre life science campus south of Cambridge, home to over 60 companies and 300 academic researchers from the Babraham Institute. Campus companies have access to nine open-access scientific facilities operated by the Babraham Institute, including flow cytometry, genomics sequencing,…
Synthetic glycan-targeted small molecules for next-generation immunotherapy
Anomer Bio is a biotechnology company developing synthetic monosaccharides and small molecule drugs that target glycans, the sugars coating cell surfaces that influence immune responses and disease. Its platform combines multi-omics data and machine learning to model how cells process sugars, enabling the design of…
Small molecule therapeutics targeting PDE4 enzymes in kidney disease
Mironid is a company developing first-in-class small molecule therapeutics for autosomal dominant polycystic kidney disease, one of the most common hereditary kidney disorders. Its lead programme targets long-form PDE4 enzymes to modulate cyclic AMP signalling, the central driver of cyst growth across all disease…
Herpesvirus-vectored vaccines for livestock and companion animals
The Vaccine Group develops recombinant herpesvirus-vectored vaccines against infectious diseases affecting livestock and companion animals. Its modular platform is designed to generate durable immune responses in young animals, including those carrying maternally derived antibodies. Development programmes include…
Preclinical in vitro bioassay CRO for drug discovery programmes
Cellomatics Biosciences is a UK-based contract research organisation providing bespoke preclinical in vitro bioassay services to biotechnology and pharmaceutical clients. The company specialises in cell-based assays, phenotypic screening, target validation, and toxicity profiling across oncology, immuno-oncology,…
Global pharma company in oncology, immunology, and neuroscience
Johnson & Johnson is a multinational pharmaceutical company with UK operations spanning commercial, medical affairs, and innovation activities. Its Innovative Medicine division covers oncology, immunology, neuroscience, and infectious disease. The company operates an EMEA Innovation Centre in London focused on…
Dendritic cell biology platform for cancer and autoimmune therapies
Adendra Therapeutics is a discovery-stage biotechnology company developing small molecule and biologic medicines targeting dendritic cell biology for the treatment of solid tumours and autoimmune diseases. The company's approach is based on research into how dendritic cells regulate adaptive immune responses to cell…
Biotech venture builder co-creating and scaling drug discovery companies
Molecule to Medicine (MTM) is a biotech venture builder that co-creates, builds, and scales drug discovery companies within a shared operational ecosystem, combining drug discovery expertise with shared infrastructure to enable rapid company formation. UK operations are based at Milton Park, Abingdon, with a further…
CSF-1R antibody therapy for tenosynovial giant cell tumour
SynOx Therapeutics is a late-stage biopharmaceutical company developing emactuzumab, a humanised monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumour and other macrophage-driven conditions. Emactuzumab was licensed from Roche and inhibits the CSF-1 receptor to deplete…
Global pharmaceutical company developing medicines across major disease areas
AstraZeneca is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of prescription medicines. Its pipeline and product portfolio span oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases, and vaccines. The company…
Cancer immunotherapies targeting novel antigens from the dark genome
Enara Bio is a clinical-stage biopharmaceutical company developing cancer immunotherapies directed against Dark Antigens, a class of cancer-specific targets derived from previously uncharted genomic dark matter. Its platform integrates bioinformatics, immunopeptidomics, and immunology to discover and validate novel…
Small molecule GPR65 inhibitors restoring immune response in solid tumours
Pathios Therapeutics is a clinical-stage drug discovery company developing small molecule inhibitors of GPR65, a pH-sensing G protein-coupled receptor that drives immunosuppressive polarisation of tumour-associated macrophages in the acidic tumour microenvironment. By blocking GPR65, Pathios aims to restore…
Precision oncology drugs and vaccines for cold tumours
IngenOx Therapeutics Limited is a clinical-stage biopharmaceutical company developing precision oncology drugs and cancer vaccines for difficult-to-treat tumours. The company serves oncology patients and clinical development partners through a pipeline spanning small molecule immunomodulators, PRMT5 inhibition and…
Oral small molecule therapies for rare hereditary diseases
KalVista Pharmaceuticals is a biopharmaceutical company specialising in the discovery and commercialisation of oral small molecule protease inhibitors for rare diseases with significant unmet need. The company's lead programme targets the kallikrein-kinin system and has produced an approved oral on-demand therapy for…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…
Small molecule therapeutics targeting lipid-signalling pathways
Artelo Biosciences is a clinical-stage biopharmaceutical company developing small molecule therapeutics that modulate lipid-signalling pathways, including the endocannabinoid system. Its pipeline includes ART27.13, a peripherally selective cannabinoid receptor agonist in Phase 2 for cancer-associated anorexia and…